These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://kaitlynslit181024.diowebhost.com/94171680/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide